Vertex Pharmaceuticals recently reported positive clinical trial data for povetacicept in IgA nephropathy and primary ...
Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN) There are currently no therapies ...
Povetacicept is an investigational dual BAFF and APRIL inhibitor being tested for various glomerulonephritis types in clinical trials.
The MarketWatch News Department was not involved in the creation of this content. EXTON, PA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The membranous nephropathy (MN) treatment paradigm is on the brink of ...
Company intends to advance felzartamab into late-stage development in Primary Membranous Nephropathy and other autoantibody-driven immune-mediated diseases Primary Membranous Nephropathy is a rare, ...
Nearly 1 in 5 membranous nephropathy patients never achieve remission, and nearly one-third of those that do will relapse. NEWTON, Mass., May 24, 2023 /PRNewswire/ -- Membranous nephropathy (MN) is a ...
What is your role in the study? Dr. Cattran: Dr. Fernando Fervenza of the Mayo Clinic [Rochester, Minn.] and I are the two principal investigators of this trial. We are testing in an open-label, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback